Journal
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 12, Issue 6, Pages 498-508Publisher
HONG KONG ASIAMED PUBLISH HOUSE
DOI: 10.1016/j.ajps.2017.05.006
Keywords
Mitochondria-targeting; Liposomes; DQAsomes; Nanoparticles; Cancer; Diabetes
Categories
Funding
- National Natural Science Foundation of China [81473162]
- Program for Liaoning Excellent Talents in University
- Young and middle-aged career development planning of Shenyang Pharmaceutical University
Ask authors/readers for more resources
Mitochondria are a novel and promising therapeutic target for diagnosis, treatment and prevention of a lot of human diseases such as cancer, metabolic diseases and neurodegenerative disease. Owing to the mitochondrial special bilayer structure and highly negative potential nature, therapeutic molecules have multiple difficulties in reaching mitochondria. To overcome multiple barriers for targeting mitochondria, the researchers developed various pharmaceutical preparations such as liposomes, polymeric nanoparticles and inorganic nanoparticles modified by mitochondriotropic moieties like dequalinium (DQA), triphenylphosphonium (TPP), mitochondrial penetrating peptides (MPPs) and mitochondrial protein import machinery that allowspecific targeting. The targeted formulations exhibited enhanced pharmacological effect and better therapeutic effect than their untargeted counterpart both in vitro and in vivo. Nanocarriers may be used for bio-therapeutic delivery into specific mitochondria that possess a great potential treatment of mitochondria related diseases. (C) 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available